YEM Search

搜索结果

PTPN2

靶点ID:TCMBANKGE000757

靶点别名:PTN2; PTPT; TC-PTP; TCELLPTP; TCPTP

靶点描述:protein tyrosine phosphatase non-receptor type 2

染色体:18

染色体位置:18p11.21

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:9650

OMIM_Link:176887

Ensembl_Link:ENSG00000175354

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN001688	11-keto-β-boswellic acid		C30H46O4		CC1CCC2(CCC3(C(=CC(=O)C4C3(CCC5C4(CCC(C5(C)C(=O)O)O)C)C)C2C1C)C)C
TCMBANKIN022405	deoxyoleanolic acid	AC1LDIL3; Deoxyoleanolic acid; MXEMKMNFLXVQBW-UHFFFAOYSA-N; 2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid	C30H48O2	440.7 g/mol	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCCC5(C)C)C)C)C2C1)C)C(=O)O)C
TCMBANKIN034976	Oleanic acid	oleanolic acid; oleanoic,acid; oleanic acid	C30H48O3	456.7	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C
TCMBANKIN036828	Wedelolactone	NCGC00163667-01; N2131; UNII-0K6L725GNS; 1,8,9-Trihydroxy-3-methoxycoumestan; Ambotz524-12-9; CTK8G3781; 0K6L725GNS; Wedelolactone, European Pharmacopoeia (EP) Reference Standard; SC-67595; ZINC6483512; IKK Inhibitor II, Wedelolactone; GTPL5551; CCG-208289; NCGC00163667-02; SR-05000002318-2; Wedelolactone, >=98% (HPLC), powder; 7-Methoxy-5,11,12-trihydroxy-coumestan; AKOS015897173; AN-45548; C10541; AC1NQZ4Z; CHEMBL97453; BRD-K53635676-001-02-3; 1,8,9-Trihydroxy-3-methoxy-benzo[4,5]furo[3,2-c]chromen-6-one; 7-Methoxy-5,11,12-trihydroxycoumestan; CHEBI:10037; DTXSID60200408; 1,8,9-trihydroxy-3-methoxy-6-benzofurano[3,2-c]chromenone; W4016_SIGMA; Wedelolactone, <i>Eclipta alba; FT-0698529; SCHEMBL601220; MFCD07778564; SR-05000002318; CM-842; 5,11,12-Trihydroxy-7-methoxycoumestan; K00058; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; NCGC00163667-03; Wedelolactone, Eclipta alba; BRD-K53635676-001-01-5; 7-methoxy-5,11,12-trihydroxy-coumestan; Wedelolactone; 524W129; SMP2_000112; 1,8,9-trihydroxy-3-methoxy-benzofurano[3,2-c]chromen-6-one; 1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one; 524-12-9; MolPort-003-960-187; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 1,8,9-trihydroxy-3-methoxy-; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; HMS2043P19; LMPK12090046; D0F8QJ; BDBM50096619; Wedelolactone, analytical standard; I07-0266; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,1,8,9-trihydroxy-3-methoxy-; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 1,8,9-trihydroxy-3-methoxy-[1]benzoxolo[3,2-c]chromen-6-one; Wedelolactone; 7-Methoxy-5,11,12-trihydroxy-coumestan	C16H10O7	314.246	c1(O[H])c([H])c(c(C(=O)Oc(c([H])c(OC([H])([H])[H])c([H])c2O[H])c23)c3o4)c4c([H])c1O[H]
TCMBANKIN057923	glycin	Tocris-0219; G5417_SIGMA; WLN: Z1VQ; LS-218; 56-40-6; Glycosthene; G7126_SIGMA; Hgly; Glycine-UL-14C hydrochloride; EINECS 200-272-2; Padil; Polyglycine II; AB-131/40217813; Acido aminoacetico [INN-Spanish]; Glycine [INN]; G7403_SIGMA; CCRIS 5915; GLY (IUPAC abbrev); W328707_ALDRICH; Glycine-2-3H; G3649_SIGMA; InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5; Glycine iron sulphate (1:1); NSC 25936; P8791_SIGMA; Leimzucker; Gyn-Hydralin; D00011; Aminoessigsaeure; 50046_FLUKA; Acidum aminoaceticum [INN-Latin]; Aminoethanoic acid; aminoacetic acid; AI3-04085; 33242-26-1; H2N-CH2-COOH; C00037; G8898_SIGMA; Glyzin; G0398_SIGMA; Amitone; Hampshire glycine; Glycocoll; G5523_SIGMA; Acide aminoacetique [INN-French]; Glycine-carboxy-14C hydrochloride; Glicina [INN-Spanish]; Glycinum [INN-Latin]; Glykokoll; ST5213923; 15527_RIEDEL; 7490-95-1; NChemBio.2007.13-comp1; Glycine, non-medical; BPBio1_001222; Biomol-NT_000195; 57678-19-0; Glycolixir; 63183-41-5; 87867-94-5; HSDB 495; AIDS071643; FEMA No. 3287; CHEBI:15428; 33226_RIEDEL; Sucre de gelatine; 17829-66-2; 410225_SIAL; NCGC00024503-01; 2-Aminoacetic acid; Aminoazijnzuur; NSC25936; Glycine (JP15/USP); polyglycine; 52955-63-2; carbonocyanidic acid; 32817-15-5; 2-aminoethanoic acid; Aciport; L-Glycine; Glicoamin; 25718-94-9; Acetic acid, amino-; G8790_SIGMA; AIDS-071643; NCGC00024503-02; Glycine, homopolymer (VAN); glycine;CHEMBL451140; N'-[N-(2a,3b-Dihydroxy-12-oleanen-28-oyl)-L-alanyl]-glycine; 2-[[(2S)-2-[[(4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-10,11-dihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]amino]propanoyl]amino]acetic acid;GLY	C2H5NO2	75.07 g/mol	C(C(=O)O)N
TCMBANKIN059612	3-oxo-olean-12-en-28-oicacid		C30H46O3	454.7 g/mol	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(=O)C5(C)C)C)C)C2C1)C)C(=O)O)C
TCMBANKIN060545	Uosolic Acid		C30H48O3	456.7 g/mol	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C(=O)O
TCMBANKIN061202	Butanol		C4H10O	74.12 g/mol	CCCCO

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000009	Neoplasms	Abnormality of the nervous system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000023	Skin and Connective Tissue Diseases; Immune System Diseases	Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI000061	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI000078	Neoplasms; Skin and Connective Tissue Diseases	Abnormality of the integument; Neoplasm	Neoplastic Process	group
TCMBANKDI002512	Digestive System Diseases	Abnormality of the digestive system; Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI002974	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI003248	Nutritional and Metabolic Diseases; Endocrine System Diseases	Abnormality of metabolism/homeostasis; Abnormality of the endocrine system	Disease or Syndrome	disease
TCMBANKDI003353	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI004953	-	-	Neoplastic Process	disease
TCMBANKDI007737	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI007964	Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms	Abnormality of the nervous system	Mental or Behavioral Dysfunction	group
TCMBANKDI009571	Cardiovascular Diseases	Abnormality of the cardiovascular system	Disease or Syndrome	disease
TCMBANKDI009951	Nutritional and Metabolic Diseases; Musculoskeletal Diseases	Abnormality of the skeletal system	Disease or Syndrome	disease
TCMBANKDI011052	Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases	-	Disease or Syndrome	disease
TCMBANKDI011743	Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI011758	-	-	Laboratory Procedure	phenotype
TCMBANKDI014623	Eye Diseases	Abnormality of the immune system; Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI015238	Musculoskeletal Diseases	-	Disease or Syndrome	disease
TCMBANKDI015449	Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases	-	Neoplastic Process	disease
TCMBANKDI015452	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI016429	Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases	Abnormality of the skeletal system	Disease or Syndrome	disease
TCMBANKDI017024	Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI020794	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Disease or Syndrome	disease
TCMBANKDI020911	Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases	-	Disease or Syndrome	disease
TCMBANKDI023140	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI024381	Stomatognathic Diseases	Abnormality of head or neck	Anatomical Abnormality	disease
TCMBANKDI026029	-	-	Disease or Syndrome	disease
TCMBANKDI027339	Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases	Neoplasm; Abnormality of blood and blood-forming tissues	Neoplastic Process	disease
TCMBANKDI029899	Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases	Neoplasm; Abnormality of blood and blood-forming tissues	Neoplastic Process	group
TCMBANKDI031083	-	Abnormality of the skeletal system	Finding	phenotype
TCMBANKDI032062	Neoplasms; Nervous System Diseases	-	Neoplastic Process	disease